Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell ly...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:N Engl J Med
Asıl Yazarlar: Wang, Michael L., Rule, Simon, Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S., Jurczak, Wojciech, Advani, Ranjana H., Romaguera, Jorge E., Williams, Michael E., Barrientos, Jacqueline C., Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E., Li, Lei, Zhang, Liang, Newberry, Kate, Ou, Zhishuo, Cheng, Nancy, Fang, Bingliang, McGreivy, Jesse, Clow, Fong, Buggy, Joseph J., Chang, Betty Y., Beaupre, Darrin M., Kunkel, Lori A., Blum, Kristie A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4513941/
https://ncbi.nlm.nih.gov/pubmed/23782157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1306220
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller